Invitrogen-ABI merger gets EU nod

Written byBob Grant

| 1 min read

Listen with Speechify

0:00

1:00

Life science supply companies linkurl:Invitrogen Corp.;http://phx.corporate-ir.net/phoenix.zhtml?c=61498&p=irol-newsArticle&ID=1225184&highlight= and linkurl:Applied Biosystems Inc.;http://press.appliedbiosystems.com/corpcomm/applerapress.nsf/ABIDisplayPress/C40ECB8CD7236C56882574FE0064780C?OpenDocument&type=abi (ABI) announced today (Nov. 11) that their linkurl:impending merger;http://www.the-scientist.com/blog/display/55163/ has cleared its final regulatory hurdle, and that the joining of the two companies will be finalized by the end of next week. In a last step on the march towards merger, the two companies received approval from the European Commission. The companies had already received antitrust clearance from the US government. Now all that remains to be done is for every ABI shareholder to specify in writing how they'll receive compensation for their ABI shares - cash, shares in the new company, or a mixture - by the end of business next Wednesday. Both companies expect the merger to be finalized by Friday (Nov. 21).

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here

Meet the Author

Bob Grant
From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.
View Full Profile